Comparison. Research use only.
BPC-157 vs TB-500
The most commonly paired compounds in tissue-repair research, and the most commonly conflated. BPC-157 is a 15-amino-acid sequence derived from a gastric protein; TB-500 is a synthetic fragment of thymosin beta-4, not the full protein. Their mechanisms are distinct: BPC-157 acts largely through growth factor and nitric oxide pathways, while thymosin beta-4 sequesters actin and influences cell migration.
What is the difference between BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid peptide from a human gastric protein sequence, studied for growth factor (VEGFR2) and nitric oxide signalling. TB-500 is a short synthetic fragment of thymosin beta-4, characterized as the acetylated 17-23 fragment (Ac-LKKTETQ), whose parent protein sequesters actin and influences cell migration. Neither BPC-157 nor TB-500 has published human clinical trials; both evidence bases are preclinical.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Identity | Synthetic pentadecapeptide from the human gastric juice protein BPC | Fragment of thymosin beta-4, characterized as Ac-LKKTETQ, residues 17-23 (Esposito et al., 2012) |
| Length | 15 amino acids | 7 amino acids (fragment); the parent protein is 43 residues |
| Proposed mechanism | VEGFR2 upregulation, nitric oxide modulation, FAK-paxillin activation; receptor not identified | Parent protein binds G-actin one-to-one and buffers actin polymerization; ILK activation reported in cardiac cells |
| What the evidence was generated with | BPC-157 itself, in rat and mouse models | Mostly the full-length parent protein, not the TB-500 fragment |
| Human evidence | No completed human clinical trials published | None for TB-500; no product in the family has completed a successful Phase 3 program |
| WADA | S0 (Non-Approved Substances) since 2023 | S2, prohibited at all times |
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, taken from a conserved sequence within the human gastric juice protein BPC. It is unusually stable in gastric acid, plasma, and tissue (hence the name 'stable gastric pentadecapeptide'), which sets it apart from most endogenous peptides.
Read the full BPC-157 research summary →What is TB-500?
The full-length parent protein from which TB-500 is derived is the main peptide inside eukaryotic cells that sequesters G-actin, meaning it holds single actin units in reserve so they are not built into filaments. It binds monomeric G-actin one-to-one through a conserved actin-binding motif.
Read the full TB-500 research summary →BPC-157 and TB-500 specifications
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43-residue protein. Analytical work (Esposito et al., Drug Testing and Analysis 2012) characterized material sold as TB-500 as the N-terminal acetylated 17-23 fragment, Ac-LKKTETQ. Most published thymosin beta-4 biology, including actin sequestration and cardiac ILK activation (Bock-Marquette et al., Nature 2004), used the full-length protein, so those findings should not be assumed to apply to TB-500. BPC-157 has no such parent-fragment ambiguity.
Do BPC-157 and TB-500 work the same way?
No. BPC-157's receptor has not been identified; rodent studies link it to VEGFR2 upregulation, nitric oxide synthase modulation and FAK-paxillin signalling. TB-500's parent protein, thymosin beta-4, binds monomeric G-actin one-to-one and buffers the actin pool that governs cell movement. Both appear in tissue-repair research, but mechanistic work on the isolated TB-500 fragment is much thinner than on BPC-157.
Have BPC-157 or TB-500 been studied in humans?
No completed human clinical trials of BPC-157 have been published; its tendon and gastric findings come from rat models such as Staresinic et al. (2003). No human trials of TB-500 appear in our research data either, and no product in the thymosin beta-4 family has completed a successful Phase 3 program. Both BPC-157 and TB-500 remain research chemicals with no approved therapeutic use.
Why are BPC-157 and TB-500 compared?
BPC-157 and TB-500 are the two compounds most often discussed together in tissue-repair research, and both have shown activity in preclinical tendon and muscle healing models. They are also frequently conflated. The comparison matters because they differ in origin, size, mechanism and anti-doping classification: WADA lists BPC-157 under S0 and TB-500 under S2.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →